EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Transient Changes in Serum CEA, CA19-9, CRP, YKL-40, and IL-6 during Adjuvant Chemotherapy and Survival of Patients with Colorectal Cancer

Kaisa Lehtomäki iD, Eetu Heervä iD, Pirkko-Liisa Kellokumpu-Lehtinen, Harri Mustonen, Tapio Salminen, Heikki Joensuu, Kethe Hermunen, Mogens Karsbøl Boisen iD, Julia Sidenius Johansen iD, Caj Haglund, Pia Osterlund iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24076753 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Kaisa Lehtomäki und 10 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Health Technology, Tampere University, Arvo Ylpön katu 34, 33520 Tampere, Finland. Hauptthemen laut MEDLINE: CA-19-9 Antigen, Colorectal Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Finska Läkaresällskapet, Finnish Cancer Foundation, Competitive State Research Financing of the Expert Responsibility Area of Tampere, Helsinki, and Turku.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Serum carcinoembryonic antigen (CEA) is frequently monitored to detect colorectal cancer (CRC) recurrence after surgery. The clinical significance of transiently increased CEA during adjuvant chemotherapy is poorly understood. Serum CEA, CA19-9, CRP, YKL-40, and IL-6 were measured before, during, and after adjuvant 5-fluorouracil-based chemotherapy in the randomised LIPSYT study population. The biomarker kinetic patterns were classified into three groups: no increase, a transient increase (≥10% increase followed by a decrease), and a persistent increase during the adjuvant treatment, and the associations of these patterns with disease free-survival (DFS) and overall survival (OS) were investigated by using Cox regression analyses. The findings were validated in two single-centre cohorts that received modern adjuvant chemotherapy. A transient increase in CEA occurred in about a half of the patients during chemotherapy, in all the cohorts. The patients with a transient increase had a roughly similar DFS and OS to the patients with no increase, and a more favourable survival compared to the patients with a persistent increase. In the LIPSYT cohort, the hazard ratio was 0.21 for DFS (CI95% 0.07–0.66) and 0.24 for OS (CI95% 0.08–0.76). Transient increases in CA19-9 and YKL-40 tended to be associated with a favourable survival. A transient increase in CEA during adjuvant chemotherapy is associated with a favourable survival when compared with a persistent increase.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CA-19-9 AntigenColorectal NeoplasmsHumansCarcinoembryonic AntigenInterleukin-6Chitinase-3-Like Protein 1Neoplasm Recurrence, LocalChemotherapy, AdjuvantBiomarkers, Tumor

Stichwörter der Autor:innen

C-reactive proteinCA19-9CEAIL-6YKL-40adjuvant chemotherapybiomarkercolorectal cancertransient increase

Substanzen

CA-19-9 AntigenCarcinoembryonic AntigenInterleukin-6Chitinase-3-Like Protein 1Biomarkers, Tumor

Autor:innen und Institutionen

  • Faculty of Medicine and Health Technology, Tampere University, Arvo Ylpön katu 34, 33520 Tampere, Finland.
  • Department of Oncology: Tays Cancer Center, Tampere University Hospital, Teiskontie 35, 33520 Tampere, Finland.
  • Department of Oncology, Turku University Hospital, Hämeentie 11, 20520 Turku, Finland.
  • Department of Oncology, University of Turku, Kiinanmyllynkatu 10, 20520 Turku, Finland.
  • Research, Development and Innovation Center, Tampere University Hospital, Teiskontie 35, 33520 Tampere, Finland.
  • Department of Surgery, Helsinki University Hospital and University of Helsinki, Haartmaninkatu 4, 00290 Helsinki, Finland.

ORCID-Profile: Kaisa Lehtomäki, Eetu Heervä, Mogens Karsbøl Boisen, Julia Sidenius Johansen, Pia Osterlund

Förderung

  • Finska Läkaresällskapet
  • Finnish Cancer Foundation
  • Competitive State Research Financing of the Expert Responsibility Area of Tampere, Helsinki, and Turku
  • Tampere University Hospital
  • Relander's Foundation
  • Relander’s Foundation

Zitieren

APA

Lehtomäki, K., Heervä, E., Kellokumpu-Lehtinen, P. L., Mustonen, H., Salminen, T., Joensuu, H., Hermunen, K., Boisen, M. K., Johansen, J. S., Haglund, C., & Osterlund, P. (2023). Transient Changes in Serum CEA, CA19-9, CRP, YKL-40, and IL-6 during Adjuvant Chemotherapy and Survival of Patients with Colorectal Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24076753

Vancouver

Lehtomäki K, Heervä E, Kellokumpu-Lehtinen PL, Mustonen H, Salminen T, Joensuu H, et al. Transient Changes in Serum CEA, CA19-9, CRP, YKL-40, and IL-6 during Adjuvant Chemotherapy and Survival of Patients with Colorectal Cancer. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24076753

BibTeX
@article{Lehtomki2023,
  author = {Lehtomäki, Kaisa and Heervä, Eetu and Kellokumpu-Lehtinen, Pirkko-Liisa and Mustonen, Harri and Salminen, Tapio and Joensuu, Heikki and Hermunen, Kethe and Boisen, Mogens Karsbøl and Johansen, Julia Sidenius and Haglund, Caj and Osterlund, Pia},
  title = {Transient Changes in Serum CEA, CA19-9, CRP, YKL-40, and IL-6 during Adjuvant Chemotherapy and Survival of Patients with Colorectal Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24076753}
}
Kostenlos starten →